If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...
EPFO 3.0 aims to modernize provident fund services through upgraded technology, faster claim processing, simplified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results